ProCE Banner Activity

RUBY Post Hoc Analysis: Survival Outcomes With Dostarlimab Plus Chemotherapy by Type of MMR Deficiency in Patients With Endometrial Cancer

Conference Coverage
Slideset

Post hoc analysis of the phase III RUBY trial found that dostarlimab plus chemotherapy improved survival outcomes among patients with dMMR/MSI-H endometrial cancer regardless of the type of alteration that leads to dMMR or MSI-H. 

Released: June 25, 2024

Expiration: June 24, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from GSK.

GSK